In addition to the KRAS and SALL4oncogenes, CGS4 tumors highly express cancer-testis antigens (CTAs) such as MAGEA3 and MAGEA12, indicating that they might be good candidates for testing CTA-mediated cancer vaccine therapy [67]. This evidence concerns the gene MAGEA3 and cancer.